Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Randomised, Parallel-group, Placebo-controlled Study of the Safety, Tolerability and Efficacy Following Sequential Dose Regimens of Lu 31-130 to Patients With Schizophrenia

NCT00768326 is registered in ClinicalTrials.gov with H. Lundbeck A/S as lead sponsor.

NCT NCT00768326
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00768326 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Randomised, Parallel-group, Placebo-controlled Study of the Safety, Tolerability and Efficacy Following Sequential Dose Regimens of Lu 31-130 to Patients With Schizophrenia
Lead sponsor
H. Lundbeck A/S
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2007
Completion date
November 30, 2009
Enrollment
280 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia